Le marché de la stéatohépatite non alcoolique (NASH) devrait atteindre 24 266,81 millions de dollars US d'ici 2028, contre 1 631,92 millions de dollars US en 2021 ; il devrait enregistrer un TCAC de 47,1 % de 2021 à 2028.
Dans la stéatose hépatique non alcoolique (NAFLD), la graisse s'accumule dans le foie. La stéatose hépatique non alcoolique (NAFL) et la stéatohépatite non alcoolique (NASH) sont des types de NAFLD. Lorsque l'accumulation de graisse provoque une inflammation et des dommages, elle conduit au développement de la NASH, ce qui peut entraîner une cicatrisation du foie. La cicatrisation du foie est une affection potentiellement mortelle appelée cirrhose.
Le rapport offre des informations et une analyse approfondie du marché de la stéatohépatite non alcoolique (NASH) en mettant l'accent sur divers paramètres tels que les tendances du marché, les avancées technologiques et la dynamique du marché. Il fournit également l'analyse du paysage concurrentiel des principaux acteurs du marché à travers le monde. En outre, il inclut l'impact de la pandémie de COVID-19 sur le marché dans toutes les régions. La pandémie de COVID-19 a perturbé les conditions socio-économiques de divers pays à travers le monde. En Amérique du Nord, les États-Unis ont été profondément touchés par la pandémie de COVID-19. Les lésions hépatiques sous la forme d'une augmentation des transaminases et d'une hyperbilirubinémie chez les patients atteints de COVID-19 peuvent être attribuées à quelques facteurs, notamment une maladie hépatique préexistante. La comorbidité de la stéatose hépatique non alcoolique (NAFLD) et de la NASH chez ces patients les rend sujets à des formes graves de lésions hépatiques. Compte tenu de la forte prévalence de la NAFLD dans le monde, il est de loin essentiel de reconnaître les résultats du COVID-19 chez ces patients, qui incluent le rôle des comorbidités, la progression de la maladie et la gravité du COVID. La présence de fibrose plutôt que de NASH/NAFLD est associée à de moins bons résultats cliniques et à une mortalité plus élevée chez les patients atteints de COVID-19.
L'impact de COVID-19 sur les populations de patients comorbides, y compris les personnes avec le diabète, l'obésité, la stéatose hépatique et la NASH, a déclenché le besoin de fournir des soins optimaux aux patients. Le Global Liver Institute s'est engagé à travailler avec des chercheurs et des innovateurs du monde entier pour évaluer et éclairer rapidement une réponse forte à cette pandémie. Les recherches portant sur la lutte contre la NAFLD et la NASH indiquent que la relation anticipée avec les problèmes de poids est frappante. Par conséquent, une incidence élevée de NASH exige des diagnostics et des traitements avancés, ce qui stimule la recherche et le développement sur le marché. Ainsi, la crise du COVID-19 a alimenté la croissance du marché de la stéatohépatite non alcoolique (NASH).
Perspectives stratégiques
Régions lucratives pour le marché de la stéatohépatite non alcoolique (NASH)
Perspectives du marché
Accroître les initiatives pour accroître la sensibilisation à la croissance du marché de la NASH
NASH est une condition sous-reconnue. Pour un parcours de référencement structuré et une détection précoce, il est essentiel de sensibiliser le grand public et les médecins de premier recours à cette maladie. En établissant un parcours patient clair pour les références et les campagnes de sensibilisation des patients, davantage de personnes peuvent être identifiées et envoyées à des spécialistes pour une évaluation plus approfondie. Pour sensibiliser à la NASH, le programme d'éducation NASH a lancé la campagne d'éducation publique le 12 juin 2018, observée comme la "Journée internationale de la NASH", pour sensibiliser à la NAFLD et à sa forme plus avancée, la NASH, qui touche plus de 115 millions de personnes. personnes.
NASH 24X7, une plateforme numérique visant à accroître l'exposition et la sensibilisation à l'épidémie de NASH, a fait quelques pas lors de la Journée internationale de la NASH 2019 grâce au soutien des HCP, à la sensibilisation des patients et à la programmes de presse/diffusion TV. Pour sensibiliser le public ce jour-là, NASH Crusaders of NASH 24X7 s'est associé aux meilleurs prestataires de soins de santé (HCP), en particulier les gastro-entérologues et les hépatologues, à travers l'Inde pour organiser de nombreux ateliers de sensibilisation et d'éducation à petite et grande échelle sur la santé du foie, soulignant la nécessité d'un mode de vie dans la prévention de la NAFLD/NASH.
Lors de la Journée internationale de la NASH 2020, l'American Liver Foundation s'est jointe à une communauté mondiale pour sensibiliser à la NASH avec le soutien de la Fondation Allergan. L'American Liver Foundation (ALF) pilote actuellement un programme de messagerie texte NASH, dans lequel les gens peuvent s'inscrire pour recevoir 3 messages hebdomadaires pendant 10 semaines. Les messages consistent en des hyperliens vers des ressources NASH, des faits pertinents, des quiz interactifs et des pointeurs judicieux pour l'autogestion quotidienne. L'ALF ouvrira ce système au grand public lorsque le pilote sera terminé et évalué. Il a collaboré avec le Global Liver Institute (GLI) lors de la Journée internationale de la NASH et a partagé quelques publications sur les réseaux sociaux liées aux publications de la GLI et à la page de la journée internationale de la NASH.
Ainsi, la hausse les initiatives de sensibilisation à la NASH stimulent le marché de la stéatohépatite non alcoolique (NASH).
Informations basées sur les produits
Sur la base des produits, le marché de la stéatohépatite non alcoolique (NASH) est segmenté en vitamine E et pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, et autres. En 2021, le segment des autres détenait la plus grande part de marché. Le segment selonsertib & cenicriviroc devrait enregistrer le TCAC le plus rapide de 73,3 % au cours de la période de prévision.
Marché des solutions de préservation d'organes, par produit - 2020 et 2028
Insights basés sur les applications
Sur la base des applications, le marché de la stéatohépatite non alcoolique (NASH) est divisé en traitement et diagnostic. En 2021, le segment du traitement détenait une part de marché plus importante. Cependant, le segment de traitement devrait enregistrer un TCAC plus élevé de 47,3 % au cours de la période de prévision.
Insights basés sur les canaux de vente
Sur la base du canal de vente, le marché de la stéatohépatite non alcoolique (NASH) est segmenté en pharmacie hospitalière, pharmacie de détail et fournisseur en ligne. En 2021, le segment des pharmacies de détail détenait la plus grande part du marché. De plus, le segment des pharmacies de détail devrait afficher le TCAC le plus élevé de 47,2 % au cours de la période 2021-2028.
Les acteurs du marché de la stéatohépatite non alcoolique (NASH) adoptent des stratégies organiques telles que la lancement et expansion pour étendre leur empreinte et leur portefeuille de produits dans le monde entier, ainsi que pour répondre aux demandes croissantes.
Par
Géographie< /h3>
Sur la base géographique, le marché de la stéatohépatite non alcoolique (NASH) est segmenté en Amérique du Nord (États-Unis, Canada et Mexique), Europe (Royaume-Uni, Allemagne, France, Italie, Espagne , et reste de l'Europe), Asie-Pacifique (Chine, Japon, Inde, Australie, Corée du Sud et reste de l'Asie-Pacifique), Moyen-Orient et Afrique (EAU, Arabie saoudite, Afrique du Sud et reste du Moyen-Orient et Afrique) , et Amérique du Sud et centrale (Brésil, Argentine et reste de l'Amérique du Sud et centrale).
Profils des entreprises
- Genfit SA
- One Way Liver, SL
- BioPredictive SAS
- Cadila Pharmaceuticals Ltd.
- Laboratoires Prometheus
- Siemens Healthineers AG
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Galmed Pharmaceuticals
- Laboratory Corporation of America Holdings
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are types of NAFLD. Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Key factors that are driving the growth of this market are the rising prevalence of NASH and increasing initiatives for the awareness of NASH. Additionally, the growing clinical trials involving combination studies of drugs is likely to emerge as a significant future trend in the market during the forecast period.
The CAGR value of the non-alcoholic steatohepatitis (NASH) market during the forecasted period of 2021–2028 is 47.1%.
The product segment of the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market, by product. The selonsertib & cenicriviroc segment of the non-alcoholic steatohepatitis (NASH) market is expected to witness growth in its demand at the fastest CAGR of 73.3% from 2024 to 2028.
The treatment segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 84.90% in 2021.
The retail pharmacy segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 61.39% in 2021.
The non-alcoholic steatohepatitis (NASH) market majorly consists of players such as Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings amongst others.
Intercept Pharmaceuticals, Inc and Genfit SA are the top two companies that hold huge market shares in the non-alcoholic steatohepatitis (NASH) market.
North America held the largest market share for non-alcoholic steatohepatitis in 2021. The United States held the largest market in North America for non-alcoholic steatohepatitis, and the market is expected to grow due to increasing adoption of technological advancements and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the non-alcoholic steatohepatitis market.
The presence of nonalcoholic fatty liver disease (NAFLD) and NASH in patients with COVID-19 is likely to cause them to be prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it's far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and the severity of COVID-19. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients. Additionally, there seems to be an increased likelihood of liver injury in NAFLD patients with COVID-19.
NASH had the strongest association with COVID-19 of all comorbid metabolic conditions, including hypertension and obesity. As the world keeps confronting the novel coronavirus pandemic, the impact of COVID-19 on specific patient populations, which includes people with diabetes, obesity, fatty liver disease, and NASH, has proven the need of providing actionable recommendations to clinicians and patients to offer optimal care and avoid needless deaths. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. As the push to combat NAFLD and NASH continues, research indicates that the anticipated relationship with weight problems is stark. Individuals with signs and symptoms of underlying fatty liver disease and NASH are at higher risk and infectious for longer for COVID-19. Therefore, COVID-19 is affected positively on the growth of the market.
- Genfit SA
- One Way Liver, S.L.
- BioPredictive S.A.S
- Cadila Pharmaceuticals Ltd.
- Prometheus Laboratories
- Siemens Healthineers AG
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Galmed Pharmaceuticals
- Laboratory Corporation of America Holdings
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Apr 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Apr 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Apr 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)